Results 81 to 90 of about 86,774 (206)

Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation

open access: yes, 2010
BACKGROUND: A model to predict hospitalization due to respiratory syncytial virus (RSV) of infants born at 33- 35 weeks' gestation was developed using seven risk factors from the Spanish FLIP study "birth +/-10 weeks from the beginning of the RSV season",
European, RSV Risk Factor Study Group   +12 more
core   +1 more source

ACIP Adult RSV Work Group considerations [PDF]

open access: yes
04-RSV-Adults-Melgar-508 ...

core  

Effectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events

open access: yesEmerging Infectious Diseases
We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79%
Wiegand, Ryan E.   +12 more
openaire   +3 more sources

Five Years’ Experience with Respiratory Syncytial Virus Among Hospitalized Patients: A Retrospective Study from Jazan, Saudi Arabia

open access: yesInfection and Drug Resistance
Nabil S Dhayhi,1,* Ali Aqeel,2,* Salman Ghazwani,3 Ibrahim M Gosadi,4 Haleemah Mohammed AlQassimi,5 Abdullah Thubab,6 Ibrahim Abdullah Sairam,6 Majed Ahmed Hakami,6 Fahd Ahmed Sawan,6 Sabreen Mohammed Asiry,7 Mawahib Khalifa,7 Hadi Daghreeri,8 ...
Dhayhi NS   +17 more
doaj  

Increase in febrile illness among children in mainland China, winter 2023 - 2024

open access: yesGlobal Biosecurity
In late 2023, mainland China reportedly saw a rise in respiratory illnesses, primarily among children. Officials from the Chinese Center for Disease Control attributed this increase to the circulation of known pathogens, including influenza viruses ...
Joel Keep, David Heslop
doaj   +1 more source

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine

open access: yes, 2017
International audienceRespiratory syncytial virus (RSV) is the leading cause of acute respiratory infections in children, yet no vaccine is available. The sole licensed preventive treatment against RSV is composed of a monoclonal neutralizing antibody ...
Riffault, Sabine   +10 more
core   +1 more source

RSV prevention [PDF]

open access: yesArchives of Disease in Childhood, 2000
openaire   +2 more sources

Burden of RSV infections among young children in primary care : a prospective cohort study in five European countries (2021-23)

open access: yes
: Background The majority of respiratory syncytial virus (RSV) infections in young children are managed in primary care, however, the disease burden in this setting remains poorly defined.
Raes, Marc   +16 more
core  

National respiratory syncytial virus acute respiratory infection burden of disease estimate in Mexican children under 2 years

open access: yesFrontiers in Pediatrics
BackgroundNational population-based respiratory syncytial virus (RSV) direct burden-of-disease estimates on outpatient, emergency room (ER) and hospitalization settings are scarce among Mexican children.
Rosa María Wong-Chew   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy